Nordson Corporation — Q1 FY2024 Form 10-Q
Reporting period: Three months ended January 31, 2024. Unaudited results; dollar amounts below are in millions unless noted.
Business context and results
Nordson makes precision dispensing, processing, medical fluid-management, and electronics test and inspection products. It reported sales of $633.2 million, up 3.7% year over year. Acquisitions contributed 5.4% and currency 0.5%, while organic sales declined 2.2%, mainly from continued electronics weakness.
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Sales | $633.2 million | $610.5 million |
| Gross margin | 55.0% | 53.9% |
| Operating profit / margin | $159.4 million / 25.2% | $144.2 million / 23.6% |
| Net income | $109.6 million | $104.3 million |
| Diluted EPS | $1.90 | $1.81 |
| Operating cash flow | $172.4 million | $123.3 million |
Gross-margin improvement reflected better manufacturing efficiencies and favorable mix. Higher operating profit lifted earnings, partly offset by interest expense rising to $21.4 million from $10.5 million, primarily because of higher average debt following acquisitions. The effective tax rate was 21.0%, versus 20.5%.
Segments and material changes
- Industrial Precision Solutions: Sales rose 13.8% to $354.5 million, including acquisition, organic, and currency contributions. Operating margin fell to 30.6% from 32.8%, primarily due to $5.9 million of additional ARAG-related intangible amortization.
- Medical and Fluid Solutions: Sales rose 3.4% to $159.5 million; operating margin improved to 28.9% from 25.5%, reflecting factory efficiencies and favorable mix.
- Advanced Technology Solutions: Sales fell 17.6% to $119.1 million, entirely organically, amid broad segment weakness, especially semiconductor-related dispense products. Operating margin increased to 16.0% from 11.7%; the prior-year period included $10.3 million of CyberOptics-related fees, severance, and non-cash inventory charges.
Regional sales were $274.0 million in the Americas, $179.3 million in Europe, and $179.9 million in Asia Pacific. Europe’s reported growth included a substantial acquisition contribution despite a 7.0% organic decline.
Cash, liquidity, and debt
- Cash and cash equivalents were $136.2 million at January 31, 2024, versus $115.7 million at October 31, 2023. The cash-flow statement reports a $20.5 million increase for the quarter.
- Operating cash flow was $172.4 million; capital expenditures were $7.5 million. Cash used in financing was $140.5 million, including $107.2 million of net debt repayments and $38.9 million of dividends.
- Total debt before issuance costs and discounts was $1.642 billion, compared with $1.749 billion at October 31, 2023. Current maturities were $116.6 million; long-term debt carrying value was $1.514 billion. The reported weighted-average rate on revolver and term-loan borrowings was 6.38%.
- Nordson said it was in compliance with debt covenants and expects operating cash flow, borrowing capacity, and capital-market access to be adequate for liquidity needs over the next 12 months and foreseeable future.
Outlook, risks, and contingencies
The filing provides no quantified quarterly or full-year earnings or sales guidance. Management cited ongoing electronics pressure, partly offset by growth in medical interventional, industrial, and polymer-processing product lines. Forward-looking risks include economic and market conditions, currency movements, trade and tax policy, geopolitical events, and the ability to integrate acquisitions, including ARAG and CyberOptics. ARAG’s purchase-price allocation remained preliminary, principally pending completion of income-tax assessments.
Nordson is involved in routine litigation and environmental matters. Management does not expect losses beyond recorded accruals to materially affect financial condition, results, or cash flows, while noting uncertainty in environmental remediation estimates. No material changes to the risk factors in the prior Form 10-K were reported. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether organic sales and electronics demand stabilize, particularly in Advanced Technology Solutions.
- Whether ARAG contributes as expected and how final purchase accounting, amortization, and integration affect margins.
- Debt maturities, refinancing plans, borrowing costs, and the continued ability to meet covenants and liquidity needs.
- Whether improved operating cash flow is sustained, given working-capital movements and planned capital allocation.
- Potential changes in currency, geopolitical, environmental, and other disclosed risks.